Hold at neutral weight with executable $147.48 trim trigger; Q4 FY26 print as validating catalyst
Maintain EMR at neutral weight (Hold) with executable discipline. The bearish inventory (forward EPS dependency, $5.8B short-term debt refi exposure, distribution volume deceleration, Eaton peer rotation) is real and dense, but the 21.7x forward multiple defensibly prices it in for a quality industrial compounder. The 8/20 reflection at comparable price ($154-157) with identical risk setup produced +1.6% raw / +1.2% alpha when EMR rallied, demonstrating that the structural floor ($3.71B TTM FCF, 67-year dividend streak, 53% gross margins, 19.6% operating margins, golden cross intact, all MAs stacked bullishly, raised FY26 guide at $6.55) absorbs bearish setups at these prices. Preemptively trimming within $2 of the Bollinger middle band is picking a top, not risk management. The disciplined response is Hold at neutral weight with pre-committed trim trigger at $147.48 on volume confirmation — not discretionary vague sizing — converting the passive Hold failure mode into executable discipline without paying the trim-tax.
| Position | Action |
|---|---|
| 50 SMA break ($147.48) on volume confirmation | Trim position per pre-committed trigger |
EMR is a compelling BUY based on healthy technical consolidation confirming a sustainable uptrend, reasonable forward P/E of 21.7x, real catalysts including the $2.9B BP Shah Deniz contract, accelerating earnings, and $3.7B TTM free cash flow supporting the capital return story.
| Indicator | Value | Signal |
|---|---|---|
| 50 SMA | 147.48 | bullish |
| 200 SMA | 140.53 | bullish |
| 10 EMA | 158.12 | neutral |
| RSI(14) | 55.62 | neutral |
| MACD Line | 3.71 | neutral |
| MACD Signal | 4.55 | bearish |
| MACD Histogram | -0.84 | bearish |
| Bollinger Upper Band | 167.96 | neutral |
| Bollinger Middle Band | 156.65 | neutral |
| Bollinger Lower Band | 145.33 | neutral |
| ATR(14) | 4.13 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
Forward P/E of 21.7x represents reasonable valuation; the 34.5x TTM P/E reflects temporary restructuring charges, not structural weakness
↩ rebuts: “Bear's reliance on TTM P/E as the valuation anchor”
· concedes: The MACD bearish crossover, RSI reset from 72 to 55, and trading below the 10 EMA at $158.12 are legitimate technical caution signals worth monitoring; The 34.5x TTM P/E is a valid current metric even if forward earnings are expected to normalize it; Bond market volatility and Fed policy uncertainty represent genuine near-term headwinds for cyclicals; The 52-week high at $166.35 may represent psychological resistance; The 0.90x current ratio, while structurally normal for the business model, warrants monitoring
EMR is in a distribution pattern, not a healthy consolidation — the tape shows sellers unloading into strength, momentum is deteriorating, and the risk/reward at current levels is asymmetric to the downside given stretched valuations, a fragile balance sheet, and macro headwinds.
EV: -7 to -10% · concedes: MACD is still above zero, so the long-term trend hasn't fully rolled over yet; BP Shah Deniz does represent project award momentum; EMR has thematic adjacency to secular tailwinds
→ vs conservative: Calling EMR a 'fortress balance sheet' is intellectual malpractice; current ratio 0.90 and negative $1.4B working capital contradict the characterization
→ vs conservative: Rising SMAs are a lagging indicator; price action at highs with declining volume is textbook distribution, not healthy uptrend
→ vs conservative: PEG of 1.82 looks reasonable only if $7.23 EPS forecast is correct; if wrong, valuation metrics deteriorate significantly
→ vs conservative: Waiting until Q4 FY26 to 'validate forward EPS trajectory' means buying at ~140 after the damage is done, not 157
→ vs neutral: 'Healthy consolidation' framing is dangerous complacency; consolidation at highs on declining volume is what tops look like before they break
→ vs neutral: Waiting for 50 SMA at 147.48 as entry confirmation means missing the move; if 154.72 breaks, 50 SMA gets tested within days, not weeks
| neutral |
| VWMA(30) | 159.45 | bearish |
Support: 154.72 · 150 · 151 · 147.48 · 140.53 | Resistance: 158.12 · 159.45 · 163.65 · 163.83 · 167.96
EMR exhibits a decisively bullish long-term structure with both SMAs rising and price ~11.9% above the 200 SMA, but short-term momentum has clearly cooled following a bearish MACD crossover (line below signal on 8/19–20) and RSI reset from 72 to 55.62. The stock is resting on the Bollinger middle band (156.65) after a 5.5% pullback from August highs, with support at 154.72 and the 50 SMA at 147.48, while resistance sits at the 10 EMA (158.12), VWMA (159.45), and August swing highs at 163.65–163.83. The overall bias is bullish consolidation rather than reversal—fresh volume-driven buying above 159.45 would target 163–168, while a close below 147.48 would signal the medium-term uptrend is in jeopardy.
Market Cap
$87.72B
P/E Ratio (TTM)
34.5x
Forward P/E
21.7x
PEG Ratio
1.82
P/B Ratio
4.30x
EPS (TTM)
$4.56
Forward EPS
$7.23
Dividend Yield
1.43%
Beta
1.235
52-Week High
$166.35
52-Week Low
$122.64
50-Day MA
$147.52
200-Day MA
$141.48
Revenue (Q3 FY26)
$4.562B
Diluted EPS (Q3 FY26)
$1.28
Gross Margin
53.2%
Operating Margin
26.9%
EBITDA Margin
32.5%
Net Profit Margin
13.8%
ROE
12.8%
ROA
6.9%
FCF Yield
~4.2%
Total Assets
$42.09B
Total Liabilities
$21.77B
Total Stockholders' Equity
$20.30B
Total Debt
$14.06B
Net Debt
$11.57B
Cash & Equivalents
$1.79B
Debt-to-Equity
0.68x
Current Ratio
0.90x
Working Capital
-$1.40B
Goodwill & Intangibles
$27.11B (64% of assets)
Goodwill
$18.15B
Other Intangibles
$8.95B
Tangible Book Value
-$6.80B
PP&E (Net)
$3.53B
Operating Cash Flow (TTM)
~$3.95B
Free Cash Flow (TTM)
$3.71B
CapEx (TTM)
~$430M
FCF (FY2025)
$2.667B
FCF (FY2024)
$2.913B
Revenue (FY2025)
$18.016B
Operating Income (FY2025)
$3.532B
EBITDA (FY2025)
$4.839B
Restructuring Charges (FY2025)
$350M
Interest Expense (TTM)
~$395M
Dividends Paid (TTM)
$1.22B
Buybacks (TTM)
$610M
Diluted Shares
561M
Strengths
Concerns
Emerson Electric Co. (EMR) is a high-quality industrial automation compounder with a premium valuation (34.5x TTM P/E, 21.7x forward P/E) trading near 52-week highs. The company demonstrates excellent profitability with 53.2% gross margins, 26.9% operating margins, and $3.71B TTM free cash flow, though elevated intangibles (64% of assets), a tight current ratio of 0.90x, and $5.8B in short-term debt refinancing needs present near-term risks. The forward EPS target of $7.23 implies 58% earnings expansion that must materialize to justify current valuation; investors should HOLD given quality franchise but await pullbacks to ~$147 for better risk-adjusted entry.
Macro: Fed rate policy: 85% implied probability of NO rate cuts in 2026 per Polymarket ($7.4M volume), with all cut scenarios (6, 9, 10, 11 cuts) at 0%. US recession probability at 8% (low but rising); UK at 12%; Japan at 36% (+10pp week) due to tightening spillover risk. Crude oil stabilizing post-Iran de-escalation hints. Treasury Sec. Bessent intervened to calm bond markets, pushing gold higher. China 5-Year Plan 'preps for peak oil' with focus on process automation and emissions monitoring. Walmart posted soft US sales signaling consumer caution. US equities ended Friday higher with risk-on tone returning post-Iran headline.